Current Clinical Applications of the 111In-capromab Pendetide Scan (ProstaScint® Scan, Cyt-356)

Reviews in Urology

Alan W Partin¹  Misop Han¹ 

[1] James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD

关键词: ¹¹¹In-capromab pendetide scan;    ProstaScint;    Prostate cancer;    Soft-tissue lesions;    Radiolabeled monoclonal antibody;    Lymph node;    Prostatic fossa;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Prostate-specific antigen (PSA) has been extremely helpful in the detection of new or recurrent prostate cancer. However, localization of the recurrent tumor has been challenging with currently available radiographic modalities. The 111In-capromab pendetide scan was developed to diagnose accurately and, more importantly, localize and stage a new or recurrent prostate cancer. Studies suggest that the 111In-capromab pendetide scan can provide more accurate staging of clinically localized prostate cancer prior to staging lymphadenectomy or definitive therapy. It can also provide valuable information when local adjuvant radiation therapy is considered in men with biochemical cancer recurrence following radical prostatectomy.

【 授权许可】

Unknown